BSL3 Biomedicum Core Facility - our offer
BSL3 Biomedicum Core Facility serves a growing body of researchers at Karolinska Institutet working on risk-group 3 bacteria, parasites and viruses.
BSL3 Biomedicum Core Facility has two interconnected but separate barriers approved by the Swedish Work Environment Authority to handle the following risk-group 3 pathogens within its respective barriers.
- Mycobacterium tuberculosis
- Monkeypox virus
- Chikungunya virus
- Leishmania brasiliensis, L. donovani
- Plasmodium falciparum
The facility supports various research activities integrated in its capabilities available also as a service to users. These capabilities include:
- High throughput antiviral and antibiotic screening
- Aerobiology investigative techniques
- Large-scale propagation and concentration of risk-group 3 pathogens
- In vitro infections
- 10x Genomics single-cell RNA sequencing (in collaboration with the Eukaryotic Single Cell Genomics platform at SciLifeLab, Solna)
- Cell sorting and Flow cytometry (in collaboration with Biomedicum Flow Cytometry Core)
- Various methods for pathogen inactivation and equipment decontamination, including hydrogen-peroxide vapor decontamination
- Developing new methods in BSL3
- Helping users with experiments
Support, collaborations and other initiatives
BSL3 Biomedicum receives core-facility funding from Karolinska Institutet.
The facility collaborates with SciLifeLab platforms in Solna and is open to partnerships in academia, healthcare and the private sector.
BSL3 Biomedicum is leading a Pandemic Laboratory Preparedness initiative for Swedish BSL3 laboratories: Swedish BSL3 Network